Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)
Authors not listed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2000
Abstract
The long-term safety and efficacy of galantamine (12 mg bid) will be documented during a one year open-label treatment in subjects with Alzheimer's Disease who completed the GAL-INT-8 trial (up to 400 eligible patients). Safety will be tracked by means of adverse event reports, laboratory parameters and physical exam. Long-term efficacy will be evaluated by means of a Alzheimer's Disease Assessment Scale(ADAS) and activities of daily living scale Disability Assessment for Dementia Scale(DAD)
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2000). Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8). <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00304629
Vancouver
Anonymous. Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8). Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2000.
BibTeX
@misc{anon2000LongTe,
title = {Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)},
author = {Anonymous},
journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.},
year = {2000},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Beijing Friendship Hospital 2016
Open access · US-GOV
Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease: A Multi-center Single-arm Study in China
Ai-Fu Chiou 2022
Open access · US-GOV
The Effect of NICE Support Program on Frailty and Quality of Life in Patients With Heart Failure
Ali Rezai, MD 2012
Open access · US-GOV
Deep Brain Stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer's Disease
Janssen Pharmaceutical K.K. 2011
Open access · US-GOV
Evaluation of Efficacy and Safety of Galantamine in Subjects With Dementia of Alzheimer's Type Who Failed to Benefit From Donepezil
University of Washington 2005
Open access · US-GOV
Behavioral Treatment of Nocturnal Disturbances in Alzheimer's Disease
Hull University Teaching Hospitals NHS Trust 2016
Open access · US-GOV